|
|
Influence of estrogen level on the coagulation and fibrinolysis in patients with hysteromyoma and its clinical significance |
Laboratory Medicine Center, the First Affiliated Hospital of Wenzhou Medical University, Wenzhou, 325015
|
|
Cite this article: |
XIE Yaosheng,WANG Mingshan,JIN Yanhui, et al. Influence of estrogen level on the coagulation and fibrinolysis in patients with hysteromyoma and its clinical significance[J]. JOURNAL OF WEZHOU MEDICAL UNIVERSITY, 2014, 44(5): 360-.
|
|
Abstract Objective: To explore the influence of endogenous estrogen level on the coagulation and fibrinolysis in patients with hysteromyoma and its clinical significance. Methods: Serum Estradiol (E2), prothrombin time (PT), activated partial thromboplastin time (APTT), fibrinogen (FIB), D-Dimer (D-D), activity of factor VIII (FVIII:C) and antigen of Von Willebrand Factor (VWF:Ag) were measured by one-stage recalcification clotting time assay, immunoturbidimetry assay and chromogenic substrate method in 142 patients with hysteromyoma and 80 healty controls. The patients with hysteromyoma were grouped by the quartile method with their estrogen levels and comparative analysis. Results: Compared with the controls, the PT, APTT and FIB of the patients with hysteromyoma were obviously lower, but the D-Dimer was higher (respectively, P<0.05), and there were no significant differences in serum E2, FVIII:C and vWF:Ag (respectively, P>0.05). Grouped by the endogenous estrogen level, the PT and APTT were shorter in the Q4 group of the patients with hysteromyoma than that in the other groups, and the D-Dimer was obviously higher (respectively, P<0.05), but there were no significant differences in the other parameters (respectively, P>0.05). Conclusion: The coagulation function and the secondary fibrinolytic function in the patients of hysteromyoma can relatively enhance, though there is no significant differences at the whole estradiol level in the patients of hysteromyoma, there is relatively enhancement in the coagulation and fibrinolysis in the patients of the higher estradiol level.
|
Received: 10 March 2014
|
|
|
|
|
|
|
|